While taking beta-blockers, patients with a history of
severe anaphylactic reactions to a variety of allergens may be
more reactive to repeated challenge, either accidental,
diagnostic, or therapeutic.
Such patients may be unresponsive to
the usual doses of epinephrine used to treat allergic reactions.
BETAGAN® ophthalmic solution has been shown
to be effective in lowering intraocular pressure and may be used in
patients with chronic open-angle glaucoma or ocular hypertension.
-- Abnormally low intraocular pressure often related to chronic inflammation (uveitis).
-- A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.
BETAGAN® ophthalmic solution is
contraindicated in those individuals with bronchial asthma, or with a
history of bronchial asthma, or severe chronic obstructive pulmonary
disease (see WARNINGS); sinus
bradycardia; second and third degree atrioventricular block; overt
cardiac failure (see WARNINGS);
cardiogenic shock; or hypersensitivity to any component of these
-- A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
Complete atrioventricular block
-- Complete failure of atrial electrical impulse conduction through the AV node to the ventricles.
-- inability of the heart to pump blood at an adequate rate to fill tissue metabolic requirements or the ability to do so only at an elevated filling pressure.
-- Shock resulting from diminution of cardiac output in heart disease.
-- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.
As with other topically applied ophthalmic drugs,
BETAGAN® may be absorbed systemically.
adverse reactions found with systemic administration of beta-adrenergic
blocking agents may occur with topical administration.
severe respiratory reactions and cardiac reactions, including death due
to bronchospasm in patients with asthma, and rarely death in association
with cardiac failure, have been reported with topical application of
beta-adrenergic blocking agents [See CONTRAINDICATIONS].
This web-site is for informational purposes only and is not intended as a substitute for advice from your doctor.
It should not to be used for self-diagnosis or treatment.